Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
暂无分享,去创建一个
Christopher A. Miller | Karlyne M. Reilly | R. Fulton | T. Ley | K. Deschryver | K. Reilly | H. Abel | D. Gutmann | A. Hirbe | S. Dahiya | A. Perry | Jessica C. Walrath | M. Pekmezci | E. Duncavage | Tiandao Li | Sandra A. McDonald | Xiaochung Zhang
[1] Seon-Yong Jeong,et al. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions , 2014, Oncology reports.
[2] D. Gutmann,et al. Neurofibromatosis type 1: a multidisciplinary approach to care , 2014, The Lancet Neurology.
[3] Gang Chen,et al. Mutant β-III Spectrin Causes mGluR1α Mislocalization and Functional Deficits in a Mouse Model of Spinocerebellar Ataxia Type 5 , 2014, The Journal of Neuroscience.
[4] R. Lothe,et al. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis , 2014, Neuro-oncology.
[5] Beau R. Webber,et al. Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. , 2014, The American journal of pathology.
[6] H. Gogas,et al. Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. , 2014, Cancer letters.
[7] D. Gutmann,et al. BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2014, Neuro-oncology.
[8] I. Petersen,et al. Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms , 2014, Acta Neuropathologica.
[9] Qi Zhao,et al. Spectrin: Structure, function and disease , 2013, Science China Life Sciences.
[10] D. Boldrin,et al. Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST) , 2013, PloS one.
[11] A. Lupo,et al. KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions , 2013, Current genomics.
[12] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[13] L. Johannes,et al. βIII Spectrin Regulates the Structural Integrity and the Secretory Protein Transport of the Golgi Complex* , 2012, The Journal of Biological Chemistry.
[14] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[15] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[16] S. Carroll,et al. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system , 2012, Brain Research Bulletin.
[17] D. Cooper,et al. Microarray‐based copy number analysis of neurofibromatosis type‐1 (NF1)‐associated malignant peripheral nerve sheath tumors reveals a role for Rho–GTPase pathway genes in NF1 tumorigenesis , 2012, Human mutation.
[18] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[19] Ken Chen,et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..
[20] T. de Ravel,et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors , 2011, Genes, chromosomes & cancer.
[21] B. Scheithauer,et al. Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor , 2011, Clinical Cancer Research.
[22] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[23] N. Warrington,et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. , 2010, Cancer research.
[24] A. Rojiani,et al. CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. , 2010, International journal of clinical and experimental pathology.
[25] Karlyne M. Reilly,et al. Schweinfurthin A Selectively Inhibits Proliferation and Rho Signaling in Glioma and Neurofibromatosis Type 1 Tumor Cells in a NF1-GRD–Dependent Manner , 2010, Molecular Cancer Therapeutics.
[26] M. Dutia,et al. Loss of β-III Spectrin Leads to Purkinje Cell Dysfunction Recapitulating the Behavior and Neuropathology of Spinocerebellar Ataxia Type 5 in Humans , 2010, The Journal of Neuroscience.
[27] T. Kiehl,et al. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings , 2010, Journal of Cancer Research and Clinical Oncology.
[28] G. Page,et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene , 2009, EMBO molecular medicine.
[29] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[30] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[31] S. Jhanwar,et al. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. , 2009, Anticancer research.
[32] R. Lothe,et al. Germline and somatic NF1 mutations in sporadic and NF1‐associated malignant peripheral nerve sheath tumours , 2009, The Journal of pathology.
[33] G. Hutchins,et al. Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.
[34] N. Thomas,et al. Germline and somatic NF1 gene mutations in plexiform neurofibromas , 2008, Human mutation.
[35] J. Dumanski,et al. High-Resolution DNA Copy Number Profiling of Malignant Peripheral Nerve Sheath Tumors Using Targeted Microarray-Based Comparative Genomic Hybridization , 2008, Clinical Cancer Research.
[36] A. Stemmer-Rachamimov,et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. , 2008, Cancer cell.
[37] D. Burns,et al. Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. , 2008, Cancer cell.
[38] D. Evans,et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.
[39] R. Lothe,et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours , 2006, The Journal of pathology.
[40] M. Watson,et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. , 2006, Cancer research.
[41] D. Piwnica-Worms,et al. CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.
[42] F. Tamanoi,et al. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation , 2004, Glia.
[43] I. Bièche,et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR , 2004, Molecular Cancer.
[44] M. Watson,et al. Gene Expression Profiling Reveals Unique Molecular Subtypes of Neurofibromatosis Type I‐associated and Sporadic Malignant Peripheral Nerve Sheath Tumors , 2004, Brain pathology.
[45] D. Gutmann,et al. Recent advances in neurofibromatosis type 1 , 2004, Current opinion in neurology.
[46] K. Hoffmann,et al. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors , 2004, Acta Neuropathologica.
[47] R. Lothe,et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] M. Pierotti,et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[49] M. Watson,et al. Differential NF1, p16, and EGFR Patterns by Interphase Cytogenetics (FISH) in Malignant Peripheral Nerve Sheath Tumor (MPNST) and Morphologically Similar Spindle Cell Neoplasms , 2002, Journal of neuropathology and experimental neurology.
[50] D. Burns,et al. Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.
[51] J. Barrett,et al. Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of Sox-9 transcription factor. , 2001, Rheumatology.
[52] D. Gutmann,et al. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. , 2001, The American journal of pathology.
[53] R. Lothe,et al. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors , 2001, Genes, chromosomes & cancer.
[54] Karlyne M. Reilly,et al. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.
[55] S. Colman,et al. Chromosome 17 loss‐of‐heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1 , 2000, Genes, chromosomes & cancer.
[56] Karlyne M. Reilly,et al. Mouse models of tumor development in neurofibromatosis type 1. , 1999, Science.
[57] S. Velasco-Miguel,et al. Mouse tumor model for neurofibromatosis type 1. , 1999, Science.
[58] D. Louis,et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. , 1999, The American journal of pathology.
[59] Yeang H. Ch'ng,et al. A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[60] S. Pulst,et al. Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin , 1998, Nature Genetics.
[61] P. Marynen,et al. TP53 mutations are frequent in malignant NFI tumors , 1994, Genes, chromosomes & cancer.
[62] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..
[63] National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. , 1988, Neurofibromatosis.